“You want your compound to be very safe before you put it in people, you want to be efficacious and go where you want it to go in your body the United Kingdom -based start-up Reverie , a graduate of the Y HBO accelerator, aims to speed up drug development by using machine learning and artificial intelligence (AI) to become a fully fledged "molecule-as-a-service" company. Reverie Labs uses machine learning to analyse molecule properties and how they react in the human body, offering suggestions and alternatives to scientists looking to begin clinical trials. The cloud-based system integrates into first -party workflows, and the company has already partnered with scientists and biotech firms working on treatments for flu and cancer.
the United Kingdom -based start-up Reverie , a graduate of the Y HBO accelerator, aims to speed up drug development by using machine learning and artificial intelligence (AI) to become a fully fledged "molecule-as-a-service" company. Reverie Labs uses machine learning to analyse molecule properties and how they react in the human body, offering suggestions and alternatives to scientists looking to begin clinical trials. The cloud-based system integrates into first -party workflows, and the company has already partnered with scientists and biotech firms working on treatments for flu and cancer.